107
Participants
Start Date
October 29, 2018
Primary Completion Date
August 30, 2021
Study Completion Date
June 13, 2022
CS1003 monoclonal antibody
CS1003 will be administered intravenously every 3 weeks.
Beijing Cancer Hospital, Beijing
Peking Union Medical College Hospital, Beijing
Peking University Third Hospital, Beijing
The First Hospital of Jilin University, Changchun
Hunan Cancer Hospital, Changsha
West China Hospital Sichuan University, Chengdu
Guangdong Provincial People's Hospital, Guangzhou
Zhejiang Cancer Hospital, Hangzhou
Harbin Medical University Cancer Hospital, Harbin
Yunnan Cancer Hospital, Kunming
The First Affiliated Hospital of Nanchang University, Nanchang
Huashan Hospital Fudan University, Shanghai
Shanghai East Hospital, Shanghai
Shanghai pulmonary hospital, Shanghai
Zhongshan Hospital, Shanghai
Tianjin Medical University Cancer Institute and Hospital, Tianjin
Henan Cancer Hospital, Zhengzhou
Lead Sponsor
CStone Pharmaceuticals
INDUSTRY